Sebia invites you to their event
About this event
Dr. Filipa Varela will present how anti-MCV antibodies contribute to the early and accurate diagnosis of Rheumatoid Arthritis (RA) , ultimately supporting improved patient outcomes and quality of life.
The session will explore the epidemiology and economic burden of RA, the clinical challenges along the patient journey, and the importance of early serological testing within the ACR/EULAR diagnostic framework.
Dr. Varela will provide scientific insights into anti-MCV as a next-generation ACPA marker, emphasizing its added diagnostic value in ACPA-negative and early-onset RA. She will also discuss emerging therapeutic perspectives, including the potential role of anti-MCV in disease monitoring, treatment response, and precision medicine approaches.
Hosted by
Sebia is the world’s leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic (IVD) testing.
